ISSN2456-3315
Impact Factor10.57
UGC CAREApproved
Low Cost₹599 / $45
CrossRefDOI
ESTD2016
Peer ReviewTransparent
AccessOpen
Submission: Always Open
Paper Title
A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient.
Authors
Shaila Sumaiya , Anjali Bharadwaj
Keywords
HPLC, Amlodipine Besylate, Telmisartan HCl , Chromatogram , Validation .
Abstract
The LC method for the determination of test procedures of Assay for Amlodipine Besylate and Telmisartan HCl in bulk drug, and tablets were simple, reliable, sensitive and less time consuming. The positivity of the present working procedures was a simple isocratic method. The present method can be used for rapid and precise quantification of Amlodipine Besylate and Telmisartan HCl. The present work showing a validation with highly sensitive and selective method for the estimation of Amlodipine Besylate and Telmisartan HCl in pharmaceutical dosage forms.
Full Paper, Downloads & Preview
How To Cite
Choose the style your journal or department asks for, then copy it. Every version below is generated from this paper's own record.
IJRTI — journal style
"A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient.", IJRTI - International Journal for Research Trends and Innovation (www.ijrti.org), ISSN:2456-3315, Vol.5, Issue 9, page no.7 - 22, September-2020, Available :https://ijrti.org/papers/IJRTI2009002.pdf
APA — 7th edition
Sumaiya, S., & Bharadwaj, A. (2020). A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient. International Journal for Research Trends and Innovation, 5(9), 7 - 22. https://ijrti.org/viewpaperforall.php?paper=IJRTI2009002
MLA — 9th edition
Sumaiya, Shaila, and Anjali Bharadwaj. "A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient." International Journal for Research Trends and Innovation, vol. 5, no. 9, 2020, pp. 7 - 22, https://ijrti.org/viewpaperforall.php?paper=IJRTI2009002.
Chicago — 17th, bibliography
Sumaiya, Shaila, and Anjali Bharadwaj. "A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient." International Journal for Research Trends and Innovation 5, no. 9 (2020): 7 - 22. https://ijrti.org/viewpaperforall.php?paper=IJRTI2009002.
Harvard — author–date
Sumaiya, S. and Bharadwaj, A. (2020) 'A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient', International Journal for Research Trends and Innovation, 5(9), pp. 7 - 22. Available at: https://ijrti.org/viewpaperforall.php?paper=IJRTI2009002
IEEE — numbered reference
S. Sumaiya and A. Bharadwaj, "A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient," IJRTI, vol. 5, no. 9, pp. 7 - 22, Sep. 2020.
Vancouver — biomedical
Sumaiya S, Bharadwaj A. A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient. IJRTI. 2020 Sep;5(9):7 - 22.
AMA — 11th edition
Sumaiya S, Bharadwaj A. A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient. IJRTI. 2020;5(9):7 - 22. Accessed at https://ijrti.org/viewpaperforall.php?paper=IJRTI2009002
BibTeX — Zotero, Mendeley, LaTeX
@article{IJRTI2009002,
author = {Shaila Sumaiya and Anjali Bharadwaj},
title = {A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient.},
journal = {International Journal for Research Trends and Innovation},
volume = {5},
number = {9},
pages = {7 - 22},
year = {2020},
month = {September},
issn = {2456-3315},
url = {https://ijrti.org/viewpaperforall.php?paper=IJRTI2009002}
}
RIS — EndNote, RefWorks
TY - JOUR
AU - Sumaiya, Shaila
AU - Bharadwaj, Anjali
TI - A Validated Rp-Hplc Method for Tablets Containing Amlodipine Besylate and Telmisartan Hcl as Active Pharmaceutical Ingredient.
T2 - International Journal for Research Trends and Innovation
JA - IJRTI
VL - 5
IS - 9
PY - 2020
SN - 2456-3315
UR - https://ijrti.org/viewpaperforall.php?paper=IJRTI2009002
SP - 7
EP - 22
ER -
Issue
Volume 5 Issue 9,
September-2020
Pages : 7 - 22
Other Publication Details
Paper Reg. ID
IJRTI_181341
Published Paper ID
IJRTI2009002
Downloads
205,671
Research Area
Pharmacy
Country
HYDERABAD, TELANGANA, India
Published
September 2020
Published Paper PDF
https://ijrti.org/papers/IJRTI2009002.pdf
Published Paper URL
https://ijrti.org/viewpaperforall.php?paper=IJRTI2009002
About Publisher
International Journal for Research Trends and Innovation
Published by IJRTI (JW Publication)
2456-3315
ISSN
10.57
Impact Factor
2016
ESTD Year
Open
Access
Impact Factor 10.57 calculated by Google Scholar and Semantic Scholar.
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 10.57 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
UGC CARE Approved Journal — Transparent Peer-reviewed journal aligned with UGC’s 2025 suggestive parameters, with CrossRef DOI registration and Scopus Standard metadata on every published paper.
Licence
© 2020 — Authors hold the copyright of this article.
This work is licensed under a
Creative Commons Attribution 4.0 International License
and The Open Definition.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0),
which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Disclaimer:
The content, data and findings in this article are based on the authors’ research and have been
peer-reviewed for academic purposes only. Readers are advised to verify all information before practical
or commercial use. The journal and its editorial board are not liable for any errors, losses or
consequences arising from its use.
Declarations
Funding
No external funding was received for this study.
Conflict of Interest
The authors declare that they have no conflict of interest.
Acknowledgements
The authors would like to thank the reviewers and the editorial board of International Journal for Research Trends and Innovation for their careful reading and constructive comments, and all colleagues who supported the preparation of this manuscript.
